A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Takayasu syndrome
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 07 Apr 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2017.
    • 30 Nov 2016 According to a Chugai Pharmaceutical media release, based on the results from this and GiACTA study, the company has filed an application with the Japanese Ministry of Health, Labour and Welfare (MHLW) for the approval of an additional indication of large vessel vasculitis (LVV) for the humanized anti-human IL-6 receptor monoclonal antibody, Actemra.
    • 14 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top